Enfortumab vedotin-ejfv (Padcev) plus pembrolizumab (Keytruda) showed the strongest EFS, OS, and PCR associations among neoadjuvant MIBC strategies in a network meta-analysis, although perioperative design limits attribution.
Chiara Mercinelli, MD
Advertisement
Mercinelli is a genitourinary medical oncologist at IRCCS San Raffaele Hospital and a PhD candidate in molecular medicine at Vita-Salute San Raffaele University in Milan, Italy.
Articles by Chiara Mercinelli, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Urology Times
1
Evidence for Combining Prostatic Urethral Lift With Radiotherapy
2
FDA grants breakthrough device designation to urine ID/AST panel
3
Use of prebiopsy prostate MRI increasing across US hospitals, study finds
4
Eugene Cone, MD, discusses recombinant BCG in NMIBC
5